Christopher Raymond
Stock Analyst at Piper Sandler
(2.48)
# 2,103
Out of 4,827 analysts
135
Total ratings
47.71%
Success rate
-2.26%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintains: Neutral | $135 → $115 | $118.39 | -2.86% | 21 | Apr 29, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $8 → $9 | $0.46 | +1,855.67% | 6 | Mar 6, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $122 → $126 | $59.82 | +110.63% | 15 | Feb 20, 2025 | |
| QTTB Q32 Bio | Downgrades: Neutral | $20 → $4 | $1.54 | +159.74% | 3 | Feb 11, 2025 | |
| ARDX Ardelyx | Maintains: Neutral | $7 → $8 | $3.64 | +119.78% | 7 | Jan 27, 2025 | |
| BPMC Blueprint Medicines | Maintains: Neutral | $109 → $119 | $98.76 | +20.49% | 4 | Jan 27, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $533 | $429.60 | +24.07% | 8 | Jan 27, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,195 → $1,013 | $547.67 | +84.97% | 7 | Jan 27, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $135 → $140 | $35.96 | +289.32% | 5 | Jan 13, 2025 | |
| INZY Inozyme Pharma | Maintains: Overweight | $43 → $30 | $1.24 | +2,319.35% | 1 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $42.37 | +69.93% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $212 → $220 | $185.58 | +18.55% | 11 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $3 → $13 | $1.31 | +892.37% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $75 | $6.15 | +1,119.51% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $76 | $20.25 | +275.31% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 | $0.99 | +910.10% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $10.07 | +227.71% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $7 | $2.10 | +233.33% | 2 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $6.85 | +513.14% | 1 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 | $4.98 | +341.77% | 1 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2 → $4 | $2.62 | +52.67% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $25 | $5.47 | +357.04% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $293 → $288 | $272.05 | +5.86% | 16 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $41 | $28.04 | +46.22% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $49.72 | -43.68% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $71.60 | -44.13% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $2.77 | +3,149.10% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $96 | $1.82 | +5,174.73% | 2 | Mar 13, 2020 |
Biogen
Apr 29, 2025
Maintains: Neutral
Price Target: $135 → $115
Current: $118.39
Upside: -2.86%
ALX Oncology Holdings
Mar 6, 2025
Maintains: Overweight
Price Target: $8 → $9
Current: $0.46
Upside: +1,855.67%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Overweight
Price Target: $122 → $126
Current: $59.82
Upside: +110.63%
Q32 Bio
Feb 11, 2025
Downgrades: Neutral
Price Target: $20 → $4
Current: $1.54
Upside: +159.74%
Ardelyx
Jan 27, 2025
Maintains: Neutral
Price Target: $7 → $8
Current: $3.64
Upside: +119.78%
Blueprint Medicines
Jan 27, 2025
Maintains: Neutral
Price Target: $109 → $119
Current: $98.76
Upside: +20.49%
Vertex Pharmaceuticals
Jan 27, 2025
Maintains: Overweight
Price Target: $535 → $533
Current: $429.60
Upside: +24.07%
Regeneron Pharmaceuticals
Jan 27, 2025
Maintains: Overweight
Price Target: $1,195 → $1,013
Current: $547.67
Upside: +84.97%
Ultragenyx Pharmaceutical
Jan 13, 2025
Maintains: Overweight
Price Target: $135 → $140
Current: $35.96
Upside: +289.32%
Inozyme Pharma
Jan 13, 2025
Maintains: Overweight
Price Target: $43 → $30
Current: $1.24
Upside: +2,319.35%
Jan 10, 2025
Initiates: Overweight
Price Target: $72
Current: $42.37
Upside: +69.93%
Dec 17, 2024
Maintains: Overweight
Price Target: $212 → $220
Current: $185.58
Upside: +18.55%
Nov 18, 2024
Upgrades: Overweight
Price Target: $3 → $13
Current: $1.31
Upside: +892.37%
Nov 6, 2024
Maintains: Overweight
Price Target: $60 → $75
Current: $6.15
Upside: +1,119.51%
Sep 23, 2024
Maintains: Overweight
Price Target: $66 → $76
Current: $20.25
Upside: +275.31%
Sep 3, 2024
Maintains: Overweight
Price Target: $10
Current: $0.99
Upside: +910.10%
Aug 15, 2024
Initiates: Overweight
Price Target: $33
Current: $10.07
Upside: +227.71%
Jul 1, 2024
Maintains: Overweight
Price Target: $9 → $7
Current: $2.10
Upside: +233.33%
Apr 29, 2024
Initiates: Overweight
Price Target: $42
Current: $6.85
Upside: +513.14%
Jun 12, 2023
Maintains: Overweight
Price Target: $22
Current: $4.98
Upside: +341.77%
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $2.62
Upside: +52.67%
May 12, 2023
Maintains: Overweight
Price Target: $26 → $25
Current: $5.47
Upside: +357.04%
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $272.05
Upside: +5.86%
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $28.04
Upside: +46.22%
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $49.72
Upside: -43.68%
Aug 23, 2021
Initiates: Overweight
Price Target: $40
Current: $71.60
Upside: -44.13%
Jul 12, 2021
Initiates: Neutral
Price Target: $90
Current: $2.77
Upside: +3,149.10%
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $1.82
Upside: +5,174.73%